MedTrace Logo

Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma

NCT06777290 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2025-01-15

No results posted yet for this study

Summary

The aim of the study is to compare the diagnostic performance of whole-body MRI scan, positron emission tomography + CT, and circulating tumor DNA in patients with hematologic malignancy called diffuse large cell B lymphoma (DLBCL) in staging and restaging, and prognosis.

Conditions

  • Lymphoma, Diffuse Large B-Cell

Sponsors & Collaborators

  • General University Hospital, Prague

    collaborator OTHER

  • Charles University, Czech Republic

    lead OTHER

Principal Investigators

  • Lukas Lambert, prof. M.D. Ph.D. · Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06777290 on ClinicalTrials.gov